ISB
LCTX icon

Iowa State Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Iowa State Bank’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,000
Closed -$12K – 131
2019
Q2 		$12K Hold
11,000
– – 0.01% 106
2019
Q1 		$14K Buy
11,000
+1,000
+10% +$1.24K 0.01% 103
2018
Q4 		$9K Sell
10,000
-1,430
-13% -$2.19K ﹤0.01% 101
2018
Q3 		$24K Hold
11,430
– – 0.01% 101
2018
Q2 		$21K Hold
11,430
– – 0.01% 102
2018
Q1 		$27K Hold
11,430
– – 0.01% 98
2017
Q4 		$22K Hold
11,430
– – 0.01% 96
2017
Q3 		$28K Buy
+11,430
New +$28.3K 0.01% 94

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Iowa State Bank's LCTX Position: Q3 2019 in Review

Iowa State Bank sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 11,000 shares — an estimated $12K sold.

Iowa State Bank first reported a position in LCTX in Q3 2017 and held it in 8 quarters. The position peaked at $28K in Q3 2017. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

  • Iowa State Bank reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Iowa State Bank sold 11,000 Lineage Cell Therapeutics shares in Q3 2019, an estimated $12K.
  • Iowa State Bank first reported a position in Lineage Cell Therapeutics in Q3 2017 and held it in 8 quarters.
  • Iowa State Bank's Lineage Cell Therapeutics position peaked at $28K in Q3 2017.
  • 96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on Iowa State Bank's 13F filing for Q3 2019, filed 18 Oct 2019.